Evidence map›Paper›PMID 40546462›Full record

ReviewCureus2025

Gut Microbiota as a Key Modulator of Chronic Disease: Implications for Diabetes, Autoimmunity, and Cancer.

Noor Inayat, Asma Zahir, Ahmad J Hashmat, Anusha Khan, Aftab Ahmad, Meenal Sikander, Shayan Zakir, Sabeena Ahmad, Saira K Awan, Syed S Raza and 1 more

Abstract readReview
In one paragraph

Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Host-Microbiome Interaction in the Intensive Care Unit.Diseases (Basel, Switzerland) · 2025
    Review
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Noor InayatInternal Medicine, Khyber Medical University Institute of Medical Sciences, Kohat, PAK.
Asma ZahirInternal Medicine, Hayatabad Medical Complex Peshawar, Peshawar, PAK.
Ahmad J HashmatInternal Medicine, Richmond University Medical Center, Staten Island, USA.
Anusha KhanMedical Ethics, Northwell Health, Long Island Jewish Medical Center, New Hyde Park, USA.
Aftab AhmadGeneral Medicine, Cork University Hospital, Cork, IRL.
Meenal SikanderMedicine, Rehman Medical Institute, Peshawar, PAK.
Shayan ZakirAnesthesiology, University of Virginia Medical Center, Charlottesville, USA.
Sabeena AhmadOncology/Hematology, University of Virginia Medical Center, Charlottesville, USA.
Saira K AwanNeurology, Advanced Neurology P.C., Brooklyn, USA.
Syed S RazaPhysiology, Khyber Medical College/Khyber Teaching Hospital, Peshawar, PAK.
Giustino VarrassiPain Medicine, Fondazione Paolo Procacci, Rome, ITA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The gut microbiota (GM) represents an intricate, dynamic, and complex ecosystem. It plays a key role in health and disease. The GM interacts with the host and modulates various physiological functions, including metabolism, immune regulation, and neurological function. This narrative review comprehensively analyses the role of the GM in the development and progression of three major chronic conditions, namely diabetes, autoimmune disorders, and cancer. Using a structured literature search strategy across databases such as Google Scholar, PubMed, Scopus, and Web of Science, relevant studies published between 2000 and 2025 were identified and analysed. This review highlights that dysbiosis contributes significantly to the pathogenesis of these chronic conditions. In type 2 diabetes mellitus (T2DM), alterations in the GM are associated with systemic inflammation, insulin resistance, and decreased microbial diversity. Similarly, in autoimmune disorders such as rheumatoid arthritis (RA), multiple sclerosis (MS), and inflammatory bowel disease (IBD), dysbiosis disrupts immune homeostasis, which in turn causes sustained inflammation and aberrant immune responses. Lastly, dysbiosis has been linked to the onset and progression of various gastrointestinal cancers through mechanisms including chronic inflammation and the production of carcinogenic metabolites. Fecal microbiota transplantation (FMT), probiotics, prebiotics, and dietary modifications are being explored for their potential to restore microbial balance and improve clinical outcomes. In conclusion, this review highlights the GM's pivotal role in the pathogenesis of chronic diseases and its potential as a therapeutic target.

Indexed as

autoimmunitycancerendocrinology and diabetesgut-brain axisgut microbiota dysbiosis

Identifiers

PMID40546462
PMCPMC12182902

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.